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Summary
Aim.— To describe longitudinal trends in patients’ characteristics, management and hos-
pital outcomes over 20 years of therapy for ST-segment elevation myocardial infarction
(STEMI).
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Methods.— From 1988 to 2007, 2100 consecutive patients with STEMI were admitted within
6 hours of symptom onset to a centre with a systematic reperfusion policy. The population was
divided into three periods 1988—1996, 1996—2001 and 2001—2007.
Results.— The baseline risk of mortality increased over time (p = 0.02). Use of primary PCI
increased and the proportion not receiving reperfusion therapy decreased (from 11.4 to 4.2%,
p = 0.0001). Adjunctive use of stents and glycoprotein IIb/IIIa antagonists increased. The propor-
tion of patients achieving acute TIMI-3 ﬂow in the infarct artery increased (81 to 92%, p = 0.001),
while time from symptom onset to reperfusion decreased (240 to 205min, p < 0.0001). This was
associated with a decrease in age- and sex-adjusted in-hospital mortality from 8.9 to 7.7%
and eventually 5.4% (p < 0.01). However, the mortality of patients with cardiogenic shock was
unaffected (76, 62 and 61%, respectively, p = 0.18).
Conclusion.— Reperfusion therapy can be implemented in up to 96% of STEMI patients admitted
within 6 hours of symptom onset and this is associated with improvements in outcomes. Further
improvements are needed in the management of patients with cardiogenic shock.
© 2009 Elsevier Masson SAS. All rights reserved.
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Résumé
Objectifs.— Décrire l’évolution dans le temps des caractéristiques cliniques des patients, les
modiﬁcations dans l’usage des techniques de reperfusion et leur impact sur les événements
cardiovasculaires majeurs au cours de l’infarctus aigu du myocarde admis au cours des six
premières heures.
Méthodes et résultats.— De 1988 à 2007, 2100 patients ont été admis consécutivement pour
infarctus aigu du myocarde au cours des six premières heures. La population a été scindée en
trois périodes : 1988—1996, 1996—2001 et 2001—2007 correspondant chacune à un groupe de
700 patients. Le risque global de chaque cohorte augmente avec le temps (p = 0,02). L’utilisation
de l’angioplastie primaire augmente alors que le pourcentage de patients ne recevant pas de
traitement de reperfusion diminue avec le temps (de 11,4 à 4,2 %, p = 0,0001). L’utilisation
des stents et des inhibiteurs des récepteurs GP IIb/IIIa augmente. Le pourcentage de patients
obtenant un ﬂux TIMI 3 en phase aiguë augmente (81 à 92%, p = 0,001), avec dans le même
temps une diminution du temps entre le début de la douleur et la reperfusion effective (240
à 205minutes, p < 0,0001). La mortalité hospitalière ajustée sur le sexe et l’âge diminue de
8,9 à 7,7 % et ﬁnalement 5,4 % pour la dernière période (p < 0,01). Cependant, la mortalité des
patients admis en choc cardiogénique est restée inchangée (76, 62 et 61 %, p = 0,18).
Conclusion.— Un traitement de reperfusion a pu être appliqué à 96% des patients admis au
cours de six premières heures d’un infarctus du myocarde, permettant d’obtenir une réduction
de la mortalité hospitalière. Au cours du choc cardiogénique, la stratégie idéale de prise en
charge reste à déﬁnir.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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Mntroduction
he management of ST-segment elevation acute myocar-
ial infarction (STEMI) has evolved over the past 20 years
owards widespread and timely implementation of reper-
usion therapy for all patients admitted within 12 hours of
ymptom onset. Unfortunately, in large-scale cohort stud-
es, approximately one-third of patients fail to receive
eperfusion therapy despite being admitted within the ﬁrst
2 hours and with electrocardiographic (ECG) ST-segment
levation qualifying them for early reperfusion [1,2]. The
roportion of patients who are denied reperfusion ther-
py is even higher in the elderly population (up to 50%
eyond 75 years of age) despite the fact that these indi-
iduals are at higher risk for early mortality. Even for
atients receiving reperfusion therapies (either primary
oronary angioplasty or intravenous ﬁbrinolysis), delays to
mplementation are often longer than recommended [3,4].
P
F
ppproximately 20 years ago, in 1988, we set up a policy
f ‘‘universal reperfusion therapy’’ for patients with acute
yocardial infarction (MI) with ST-segment elevation or
ew or presumed new left bundle branch block admitted
ithin 6 hours of symptom onset [5]. The present study aims
o describe the longitudinal changes in the clinical char-
cteristics of our patients and to analyse the changes in
mplementation of, and type of, reperfusion therapies as
ell as their impact on hospital outcomes from 1988 to
007.
ethodsatient population
rom June 1988 to June 2007, 2100 consecutive unselected
atients with STEMI admitted less than 6 hours after symp-
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tom onset were treated according to a previously described
patency-oriented strategy [6]:
• primary coronary angioplasty if contraindications to ﬁb-
rinolysis were present (patients at high risk of bleeding),
uncertain diagnosis, cardiogenic shock or ideal conditions
for primary percutaneous coronary intervention (PCI),
i.e. immediate availability of the catheterization lab-
oratory permitting timely reperfusion. These patients
were admitted directly to the catheterization labora-
tory;
• pre- or in-hospital intravenous ﬁbrinolysis, using accepted
protocols, followed by routine 90-min emergency coro-
nary angiography to ascertain the patency of the
infarct-related artery. If the ﬂow was TIMI grade 2 or
0-1, rescue angioplasty was usually attempted (except
for patients randomized to clinical trials of rescue PCI or
for those with small vessels). For patients with TIMI ﬂow
grade 3 in the infarct-related artery on emergency angiog-
raphy, our policy evolved gradually from routine medical
management during the ﬁrst years to allowing, accord-
ing to operator judgement, immediate angioplasty of the
infarct artery;
• conservative medical therapy was reserved for the small
subset of patients with advanced comorbidities, limited
life expectancy and contraindications to both ﬁbrinolysis
and vascular access.
Modalities of admission were as follows: prehospital care
in a mobile intensive care unit, transfer from the emer-
gency room or another hospital, MI occurring during hospital
stay, or another modality. The diagnosis of acute MI was
based on conventional criteria: chest pain lasting more than
30min and resistant to nitrates, with typical ECG changes
(≥ 1-mV ST-segment elevation in two or more limb leads
or ≥ 2-mV ST-segment elevation in two or more contigu-
ous precordial leads on a 12-lead electrocardiogram). A
small subset of patients had typical chest pain but atyp-
ical ECG changes: minor ST-segment elevation, giant T
waves, left bundle branch block, or accessory pathways.
The diagnosis of MI was eventually conﬁrmed in every
case by the presence of elevated creatine kinase (above
twice the upper limit of normal). Angiographic patency
was deﬁned as TIMI grade 3 ﬂow in the infarct-related
vessel. Multivessel disease was deﬁned as the presence
of greater or equal to 50% lumen diameter stenosis in at
least two major epicardial arteries. The diagnosis of car-
diogenic shock was based on the combination of systolic
blood pressure of less or equal to 80mmHg despite vol-
ume expansion and treatment with inotropic drugs, signs of
acute circulatory failure (cyanosis, cold extremities, rest-
lessness, mental confusion or coma) and congestive heart
failure. All patients received at least 250mg of intravenous
aspirin and 4000 IU of unfractionated heparin (UFH), more
frequently in the emergency department or in the prehos-
pital mobile intensive care unit. Subsequently, intravenous
UFH was given for at least 48 hours (starting at 1000 IU/h),
adjusted to an activated partial thromboplastin time two to
three times the control levels. Unless otherwise indicated
(atrial ﬁbrillation, left ventricular wall mural thrombus),
treatment with UFH was stopped after catheterization if
angioplasty of the infarct-related artery was performed
during the acute phase. More recently, patients received
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lopidogrel (loading dose 300mg) before admission regard-
ess of the reperfusion modality (ﬁbrinolysis or primary PCI);
noxaparin is now given in combination with tenecteplase
ccording to the results of the Enoxaparin and Thromboly-
is Reperfusion for Acute MI Treatment (EXTRACT) trial [7].
ntil recently, abciximab was administered before admis-
ion in the catheterization laboratory for patients scheduled
or primary PCI and the infusion was followed over the
ext 12 hours [8]. The combination of ﬁbrinolysis (half
osage) and glycoprotein IIb/IIIa inhibitors was restricted
o a few patients included in speciﬁc trials (Global Uti-
ization of Streptokinase and Tissue Plasminogen Activator
or Occluded Coronary Arteries [GUSTO] V) [9]. Bare-metal
tents were used exclusively for emergency coronary angio-
lasty, and drug-eluting stents were implanted only in the
etting of randomized trials (Trial to Assess the Use of the
ypher Stent in Acute MI Treated With Angioplasty, Typhoon,
rial) [10].
For all patients, clinical, angiographic and outcome data
ere collected prospectively and entered into a database.
n particular, the various delays were collected in real-time.
or the purpose of this study, we collected ‘door-to-
ecanalization time’, deﬁned as door to TIMI-3 ﬂow for
atients achieving reperfusion.
tatistical analysis
he population was divided in three equal groups of
00 patients each, corresponding to three periods,
une 1988 to April 1996, May 1996 to May 2001 and
une 2001 to June 2007. Trends in baseline character-
stics were compared using a Cochran-Armitage trend
est for categorical variables. All continuous variables
re expressed as median and range or interquartile
nterval, and intergroup comparisons were performed
sing one-way ANOVA. When signiﬁcant differences were
ound in the global comparisons among three groups,
air-wise comparisons were made with the Tukey-Kramer
est.
A risk score for in-hospital mortality was computed
rom the baseline characteristics of the whole popula-
ion. We ﬁrst performed a bivariate analysis using Chi2
nd Student’s t tests to determine the factors predictive
f in-hospital mortality. Secondly, multivariable analysis
as performed using a stepwise linear logistic regression.
ariables included at this stage were those signiﬁcantly
inked to mortality in the bivariate analysis and the ﬁnal
odel retained 5% signiﬁcant variables using the Wald
est.
The goodness-of-ﬁt of the ﬁnal model was assessed
sing the Hosmer-Lemeshow method (the samples were
anked according to their calculated risk; they were divided
nto ten equally sized classes; and, ﬁnally, the distribu-
ion of observed and expected numbers of deaths were
ompared using the Chi2 test with eight degrees of free-he three periods was made using the Kruskall-Wallis
est.
All tests were two-tailed; a p-value < 0.05 was considered
igniﬁcant and all analyses were performed using the SAS
tatistical package (SAS Institute, North Carolina).
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Table 1 Patients’ baseline characteristics (n = 2100).
1988—1996 (n = 700) 1996—2001 (n = 700) 2001—2007 (n = 700) p value
for trend
Median age, years (IQR) 58(25—91) 58(26—102) 57(21—99) 0.73
Patients aged > 70 years (%) 19.4 23.2 19.6 0.94
Median time from pain to
admission, min (IQR)
180(120—240) 180(120—240) 160(120—240) 0.04
Women (%) 18.6 18.7 17.1 0.48
Anterior MI (%) 50.9 44.6 44.4 0.01
Risk factors (%)
Hypertension 35.8 32.3 36.3 0.84
Diabetes 12.7 14.3 14.9 0.24
Dyslipidemia 41.6 36.7 35.4 0.02
Family history of CAD 30.6 31.3 26.0 0.06
Smoker 71.4 61.9 58.3 0.001
Previous CABG (%) 2.3 2.1 2.1 0.85
Previous PTCA (%) 3.4 6.4 9.9 0.001
Previous MI (%) 11.6 10.4 7.9 0.02
Ventricular ﬁbrillation before
admission (%)
4.0 5.3 8.6 0.001
Cardiogenic shock at admission (%) 5.3 4.6 5.1 0.90
MI due to stent thrombosis (%) 0 1.7 2.9 —
Multivessel disease (%) 43.3 45.4 45.1 0.51
CABG: coronary artery bypass graft; CAD: coronary artery disease; IQR: interquartile range; MI: myocardial infarction; PTCA: percutaneous
transluminal coronary angioplasty.
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aseline characteristics
he baseline clinical characteristics of the patients in the
hree cohorts are summarized in Table 1 . Over time, while
he age and sex distribution remained stable, there were
ewer smokers (from 71.4% in the initial cohort to 61.9% and
8.3% for the latest cohort, p < 0.001) and fewer patients
ith a previous or anterior MI. There were more patients
ith a history of ventricular ﬁbrillation before admission.
onversely, the proportion of patients admitted with car-
iogenic shock remained stable (5%). The time from pain to
dmission decreased from 180 to 160min (p = 0.04). There
as a continuous increase in the proportion of patients
ith a history of coronary angioplasty (currently close to
0%), while the proportion with a history of coronary bypass
urgery remained stable (2%). The proportion of patients
ith multivessel disease was similar across the three peri-
ds. In the latest period, 20 of 700 patients (2.9% of all STEMI
atients) were admitted for an infarction complicating stent
hrombosis.
odalities and results of acute reperfusionhe various types of reperfusion therapy and adjunc-
ive antithrombotic therapies are summarized in Table 2.
he use of intravenous ﬁbrinolysis decreased steadily
ver time and was in the latest period conﬁned to
rehospital administration, which accounts for the reduc-
p
i
(
p
rion in time from symptom onset to administration of
brinolytic therapy (from 172 to 144min, p = 0.0001). Res-
ue PCI was performed in approximately one-quarter of
atients treated with ﬁbrinolysis throughout the observation
eriod.
In parallel with the reduction in use of ﬁbrinolytic ther-
py, there was an increase in the use of primary PCI,
hich was used in more than two-thirds of patients in
he latest period. For patients undergoing primary PCI,
he median door-to-reperfusion time decreased, from 50
o 45 and 40min (p = 0.0001). The increasing use of pri-
ary PCI was associated with a reduction in the proportion
f patients failing to receive reperfusion therapy, which
ecreased from 11.4 to 4.2% (p = 0.0001). Overall, 88.6, 91.0
nd 95.8% of patients received acute reperfusion therapy
ver the three consecutive periods (p = 0.001). In addi-
ion to increasing implementation of reperfusion therapy,
djunctive therapy also evolved, with a substantial increase
n the use of stents (from 3.9 to 79.4%) and intravenous
lycoprotein IIb/IIIa receptor antagonists (from 1 to 87%;
xclusively abciximab in this setting), both of which dra-
atically increased in the setting of primary PCI (p < 0.0001
or both).
On the whole, the proportion of patients with successful
oronary recanalization, i.e. those with angiographically-
roven TIMI-3 ﬂow in the infarct-related artery, steadily
ncreased over the three periods, from 81 to 87 to 92%
p = 0.001), with a shorter median time from onset of chest
ain to infarct-artery recanalization (240, 230 and 205min,
espectively, p < 0.0001).
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Table 2 Types of, delays to, and results of reperfusion therapy.
1988-1996 (n = 700) 1996-2001 (n = 700) 2001-2007 (n = 700) P value
for trend
Type of reperfusion therapy (%)
Intravenous ﬁbrinolysis 45.1 25.3 25.9 0.0001
Prehospital administration 53 50 90 —
Rescue angioplasty 25 26 28 —
Primary PCI 43.5 65.7 69.9 0.0001
No reperfusion 11.4 9.0 4.2 0.0001
Median delays to reperfusion therapy, min (IQR)
Pain to ﬁbrinolysis 172 (30—360) 165 (30—360) 144 (20—360) 0.0001
Door-to-recanalization in primary
PCI
50 (30—60) 45 (30—60) 40 (30—60) 0.0001
Modalities of primary PCI (%)
Glycoprotein IIb/IIIa inhibitors 1 32 87 0.0001
Coronary stents 3.9 48.1 79.4 0.0001
Global results on acute reperfusion (entire cohort)
Successful acute reperfusion, TIMI 3
ﬂow (%)
81 87 92 0.001
Median time from pain onset to
TIMI 3 ﬂow, min (IQR)
240(30—540) 230(55—780) 205(40—650) 0.0001
Table 3 Clinical outcomes.
Outcome 1988—1996 (n = 700) 1996—2001 (n = 700) 2001—2007 (n = 700) p value
for trend
In-hospital mortality (%)
All patients 8.9 7.7 5.4 0.01 [ok?]
In patients without cardiogenic
shock
5.1 5.1 2.4 0.01
In patients with cardiogenic shock 76 62 61 0.18
Acute reocclusion of the IRA (%) 2.4 2.7 2.4 1.0
Vascular repair surgery (%) 0.7 0.2 0.4 0.41
Transfusion rate (%) 4 0.5 1 0.0001
Intracranial hemorrhage (%) 0.6 0.1 0.3 0.35
Cardiogenic shock developing during
hospitalization (%)
2.6 2.0 1.4 0.13IRA: infarct-related artery; NS: not signiﬁcant.
Clinical outcomes
In-hospital mortality decreased from 8.9 to 7.7% and even-
tually to 5.4% (p < 0.01; Table 3). While mortality decreased
in the overwhelming majority (95%) of patients who pre-
sented without cardiogenic shock upon admission (from 5.1
to 2.4%, p = 0.01), it remained essentially unchanged in the
smaller group (5%) with cardiogenic shock (76, 62 and 61%,
respectively, p = 0.18). The percentage of patients develop-
ing cardiogenic shock during hospitalization was low with
a favourable but non-signiﬁcant trend between the three
periods (Table 3). Mortality was remarkably consistent at 7%
across subgroups deﬁned according to the mode of admis-
sion of the patient (Fig. 1) with the exception of a marked
increase in mortality for the small group of patients (n = 57,
2.7% of the whole cohort) who developed acute MI while
Figure 1. Hospital mortality according to admission modality.
MICU: mobile intensive care unit; ER: emergency room.
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tigure 2. Hospital mortality in patients with or without successful
ecanalization.
ospitalized in another department, in whom hospital mor-
ality was 19%. Hospital mortality rates in patients with or
ithout successful recanalization are described in Fig. 2.
The observed mortality according to type of reperfu-
ion therapy is shown in Fig. 3, with a 25% mortality for
atients who failed to receive reperfusion therapy and lower
n-hospital mortality for all other subsets. Among patients
ho received reperfusion therapy, mortality was lowest for
hose who had successful ﬁbrinolysis (alone or with imme-
iate PCI) or spontaneous reperfusion and was higher for
atients who required rescue PCI or underwent primary PCI.
or patients admitted with a prior cardiac arrest, mortal-
ty was much higher than for those without cardiac arrest
23.4% vs 6.33%, p < 0.001).
Acute symptomatic reocclusion of the infarct-related
rtery occurred during hospital stay at the same rate over
he three periods (17, 19 and 17 patients, i.e. 2.5% of
he patients required emergency coronary angioplasty).
he rates of severe haemorrhagic complications, including
ntracranial haemorrhage, vascular surgery at the access site
mostly femoral), did not change across the three periods.isk score for in-hospital death
sing multivariable analysis, three factors were correlated
ith increased in-hospital mortality (increasing age, multi-
essel disease and cardiogenic shock upon admission) while
igure 3. Hospital mortality according to type of reperfusion
herapy.
CI: percutaneous coronary intervention.
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nigure 4. Observed and expected hospital mortality rates from
988 to 2007.
wo were associated with improved survival (active smok-
ng and dyslipidaemia). Using these ﬁve predictors, the
odel had an excellent correlation between observed and
xpected in-hospital mortality rates (Hosmer and Lemeshow
oodness-of-ﬁt test: 0.9926). The non-parametric com-
arison of risk between the three periods (using the
um-of-scores methods) showed a continuous increase in
aseline risk over time (p = 0.02).
Using the risk score, an ‘expected’ mortality was com-
uted; the observed and expected in-hospital mortality
ates are depicted in Fig. 4. There was a continuous and
arked decrease in the ratio of observed to expected mor-
ality from 1.19 to 0.91 and 0.61.
iscussion
ith increasing use of primary PCI, it has been possible to
ffer reperfusion therapy to a greater proportion of patients
ith STEMI presenting within 6 hours of symptom onset,
hile improving time to reperfusion. We observed minor
hanges in the patients’ baseline characteristics and their
aseline mortality risk increased over time. Yet, through
reater use of reperfusion therapy and improved adjunc-
ive therapy, in-hospital mortality has decreased steadily.
espite these improvements, the mortality of patients
dmitted with cardiogenic shock remains alarmingly high,
ndicating that therapies beyond reperfusion will be needed
o reduce the short-term mortality of cardiogenic shock.
There are several important aspects to these obser-
ations. The ﬁrst concerns the feasibility of offering
eperfusion therapy to virtually all patients with STEMI
ho present early. In the most recent cohort in our study,
eperfusion therapy was provided to 96% of patients, a
ercentage well above that described in large multicen-
re series [2,11,12]. This was due largely to round-the-clock
vailability of primary PCI.
Second, overall mortality decreased steadily, which most
ikely reﬂects the combined effects of more frequent use of
eperfusion therapy, increasing use of primary PCI over ﬁbri-
olysis [13], shortened delays to reperfusion, and improved
djunctive therapies such as stents, glycoprotein IIb/IIIa
ntagonists and thienopyridines [14—16]. The in-hospital
ortality among patients without cardiogenic shock (who
epresent the overwhelming majority of the total cohort) is
ow well below 3%, a ﬁgure that will presumably be difﬁ-
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cult to improve, indicating that short-term mortality in this
patient group may very well have reached its nadir. This
does not detract from the need to improve further post-
discharge outcomes and disability, which remain substantial
[17]. It also emphasizes the importance of non-fatal end-
points during the index hospital stay as important targets
for improvement: prevention of bleeding, preservation of
left ventricular function and treatment of heart failure. We
have not collected all the medications administered dur-
ing in-hospital stay. However, patients have received all
the drugs according to the ongoing international guidelines
since 1988: ﬁrst beta-blockers, then angiotensin-converting
enzyme inhibitors, followed with statin and aspirin plus
clopidogrel for all patients. Also, continued efforts to reduce
delays to ﬁrst medical contact and subsequent delays to
reperfusion are needed as these are directly correlated to
6-month mortality [18].
Third, and in contrast, it is noteworthy that the propor-
tion of patients admitted with cardiogenic shock remained
constant, at approximately 5%, and that in-hospital mor-
tality in this patient subset exceeds 60%. The SHOCK
(SHould we emergently revascularize Occluded Coronar-
ies in cardiogenic shocK?) trial demonstrated substantial
improvements in mortality with revascularization (using
PCI or CABG) in this patient population, although this
effect was observed mostly for post-discharge mortality,
with little impact on in-hospital mortality [19—21]. This
emphasizes the need for intensive further research on novel
pathways to reduce mortality in this group of patients;
whether this will be achieved by exploring novel phar-
macological approaches [22] or by improved devices for
circulatory support [23] remains unclear. However, pre-
vention of cardiogenic shock may be equally important
as treating it. In this regard, prior studies have demon-
strated that prehospital ﬁbrinolysis (as opposed to transfer
to an interventional centre for primary PCI) is associ-
ated with a reduction in the incidence of cardiogenic
shock, particularly if prehospital ﬁbrinolysis is implemented
in the ﬁrst 2 to 3 hours after symptom onset [12,24],
which argues for keeping prehospital ﬁbrinolysis in the
a
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Table 4 Patients’ baseline characteristics according to initial
Primary angioplasty
(n = 1252)
In
ﬁb
Median age, years 59 5
Median time from pain to
admission, min
182 19
Women (%) 18 1
Anterior MI (%) 46 4
Previous CABG (%) 3
Previous PTCA (%) 8
Previous MI (%) 11
Cardiogenic shock at admission (%) 6
Ventricular ﬁbrillation before
admission (%)
8
Multivessel disease (%) 46 4
MI: myocardial infarction; CABG: coronary artery bypass graft; PTCA: p265
anagement algorithm for patients with STEMI seen very
arly.
Two additional aspects are noteworthy. The proportion
f patients admitted for STEMI because of stent throm-
osis represented a substantial group of almost 3% of all
dmissions in the cohort. Given the reports of an increased
requency of late stent thrombosis with drug-eluting stents
ompared to bare-metal stents [25—27] and the relatively
ow rate of use of drug-eluting stents at the time when this
ohort was accrued, this proportion may very well increase
urther in the future, emphasizing that stent thrombosis is
ot a trivial problem [28]. Second, the proportion of patients
dmitted for STEMI following successful prehospital resusci-
ation for cardiac arrest is growing. This most likely reﬂects
mprovements in the prehospital care of these individuals.
owever, this group continues to experience high hospital
ortality (23.4%), indicating that other issues beyond ensur-
ng timely recanalization of the infarct-related artery need
o be addressed in this very high-risk group.
mpact of admission modality on clinical
utcome
he high mortality rate (19%) observed in the small subset of
atients (n = 57) experiencing in-hospital MI while admitted
n another department is worthy of further study. The role
f delayed diagnosis and extracardiac comorbidities needs
o be explored.
mpact of reperfusion type on clinical outcome
ifferences in mortality between groups as a function of
ype of reperfusion therapy received should be interpreted
ith caution given the major differences in baseline charac-
eristics and risk (Table 4), the type of adjunctive therapies,
nd the year of enrolment in these patient subsets. In partic-
lar, the very low mortality seen in patients with successful
brinolysis followed by immediate angioplasty of the cul-
rit vessel should be viewed with caution given the negative
esults of the facilitated angioplasty strategy in the Assess-
reperfusion modality (n = 2100).
travenous
rinolysis (n = 673)
Conservative medical
therapy (n = 175)
p value
for trend
6 63 0.0001
5 174 0.006
5 29 0.0001
7 48 0.87
0.7 1 0.002
5 2 0.0002
7 11 0.03
3 3 0.0009
3 5 0.0008
1 46 0.11
ercutaneous transluminal coronary angioplasty.
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ent of the Safety and Efﬁcacy of a New Thrombolytic agent
ASSENT)-4 PCI and Facilitated Intervention with Enhanced
eperfusion Speed to Stop Events (FINESSE) trials [29,30].
esults from the Combined Abciximab REteplase Stent Study
n Acute MI (CARESS in AMI) and Trial of Routine ANgioplasty
nd Stenting after Fibrinolysis to Enhance Reperfusion in
cute MI (TRANSFER-AMI) trials suggest that for patients
eceiving ﬁbrinolytic therapy, PCI performed in the hours
ollowing may be a good option [31,32]. Indeed, in the
ecent French nationwide FAST-MI (French registry of Acute
T elevation or non-ST-elevation MI) registry, which enrolled
atients over a 1-month period in November 2005, mortal-
ty was similar for patients treated with ﬁbrinolysis (with
iberal use of subsequent PCI) and for those treated with
rimary PCI [33]. This strategy of ﬁbrinolysis and subse-
uent ‘‘regimented’’ PCI [34] using optimal pharmacological
djunctive therapy, is being compared prospectively to pri-
ary PCI in the ongoing Strategic Reperfusion Early After MI
STREAM) randomized trial. Most of the patients presenting
ith cardiogenic shock were treated with primary PCI, high-
ighting the higher rate of in-hospital mortality in this subset
f PCI patients.
omparison with historical registries
verall, our data are consistent with those of similar expe-
iences of long-term longitudinal surveys and registries of
cute MI [35,36], which concur in demonstrating an increase
n the use of reperfusion therapy and its long-term sur-
ival beneﬁt [37]. The reduction in early mortality seen in
ur study is consistent with similar ﬁndings from the USIC
000 [38] and FAST-MI French registries, and most likely
eﬂects the impact of improved adjunctive pharmacologi-
al therapy. For example, in the German Acute COronary
yndromes (ACOS) registry, the combined use of clopidogrel
nd aspirin reduced the 1-year mortality rate from 10.4 to
.1% in ﬁbrinolyzed patients and from 10.9 to 6.4% in PCI-
reated patients [39]. These ﬁndings emphasize that there
s more to the management of acute STEMI than reperfusion
herapy alone.
imitations
hese data are observational, and mirror the experience
f a single centre. They do, however, reﬂect a consecutive
nbiased population of patients with acute STEMI admitted
ithin 6 hours of symptom onset, with careful and prospec-
ive collection of time intervals and outcomes.
onclusions
here is an important lesson for clinical practice from this
ohort: the recommendation to offer reperfusion therapy to
ll eligible candidates [3,4] can be implemented in clinical
ractice to almost all patients and reduce the proportion of
on-reperfused patients to less than 5%. This is likely to have
substantial impact in reducing mortality in this frequent
nd deadly condition.
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